Mihriban Tuna

CEO, Immutrin

Mihriban is CEO of Immutrin and brings 20 years’ experience in biologics drug development across biotech and pharma.

Prior to joining Immutrin, Mihriban was Entrepreneur in Residence with Cambridge Innovation Capital and Chief Scientific Officer at Adaptate Biotherapeutics (acquired by Takeda Pharmaceutical Company), Senior Vice President, Drug Discovery, at F-star Therapeutics and an early employee at Domantis Ltd. (acquired by GSK).

Mihriban holds a BSc in Biology from Middle East Technical University, a PhD in Biochemistry from University of Sussex and an EMBA from University of Cambridge Judge Business School.